We are live on
!
Find out more
PCM
Prelude Capital Management Portfolio holdings
AUM
$1.31B
1-Year Est. Return
62.02%
This Fund
S&P 500
This Quarter
Est. Return
+1.02%
1 Year Est. Return
+62.02%
3 Year Est. Return
+164.16%
5 Year Est. Return
+274.13%
10 Year Est. Return
+2,470.2%
AUM
$1.53B
AUM Growth
-$1.13M
(-0.07%)
Cap. Flow
+$46.2M
Cap. Flow
% of AUM
3.01%
Top 10 Holdings %
Top 10 Hldgs %
22.12%
Holding
1,502
New
414
Increased
344
Reduced
260
Closed
396
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NEWR
New Relic, Inc.
NEWR
|
+$10.5M |
| 2 |
Alibaba
BABA
|
+$10.4M |
| 3 |
ATVI
Activision Blizzard
ATVI
|
+$10.3M |
| 4 |
DQ
Daqo New Energy
DQ
|
+$8.18M |
| 5 |
KE Holdings
BEKE
|
+$8.14M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Green Brick Partners
GRBK
|
+$48.6M |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$38.6M |
| 3 |
Vanguard S&P 500 ETF
VOO
|
+$35.9M |
| 4 |
JD.com
JD
|
+$13.5M |
| 5 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$12.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 14.68% |
| 2 | Healthcare | 10.56% |
| 3 | Consumer Discretionary | 9.55% |
| 4 | Industrials | 7.76% |
| 5 | Energy | 6.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1001
American Coastal Insurance
ACIC
$470M
| $85.6K | 0.01% |
+11,631
| New | +$75.3K |
|
1002
Harvard Bioscience
HBIO
$28.8M
| $84.3K | 0.01% |
1,960
+710
| +57% | +$32.8K |
|
1003
uniQure
QURE
$3.2B
| $84.1K | 0.01% |
12,534
+525
| +4% | +$4.73K |
|
1004
American Public Education
APEI
$869M
| $83K | 0.01% |
16,664
-8,021
| -32% | -$41.1K |
|
|
SLGC
1005
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| $82.6K | 0.01% |
34,560
+20,800
| +151% | +$46K |
|
1006
Alight
ALIT
$394M
| $82K | 0.01% |
+578
| New | +$97.1K |
|
1007
Nano X Imaging
NNOX
$73.8M
| $81.7K | 0.01% |
12,457
-1,696
| -12% | -$17.4K |
|
1008
Ring Energy
REI
$354M
| $79.9K | 0.01% |
+40,997
| New | +$82.2K |
|
1009
Design Therapeutics
DSGN
$897M
| $78.8K | 0.01% |
+33,400
| New | +$156K |
|
|
SOS
1010
CALL
SOS Limited
SOS
$14.4M
| $78.4K | 0.01% |
1,193
| – | – |
|
|
IVAC
1011
DELISTED
Intevac Inc
IVAC
| $76.2K | 0.01% |
24,500
+2,263
| +10% | +$7.84K |
|
|
THRX
1012
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $72.8K | ﹤0.01% |
+27,073
| New | +$106K |
|
1013
Adaptive Biotechnologies
ADPT
$4.05B
| $71.7K | ﹤0.01% |
13,156
-18,648
| -59% | -$123K |
|
|
LENZ
1014
LENZ Therapeutics
LENZ
$168M
| $71.6K | ﹤0.01% |
4,126
-1,665
| -29% | -$29K |
|
1015
Globalstar
GSAT
$10.9B
| $70.8K | ﹤0.01% |
+3,601
| New | +$64.6K |
|
|
STLN
1016
Starling Oncology, Inc. Common Stock
STLN
$616M
| $69.8K | ﹤0.01% |
49,869
+8,652
| +21% | +$8.96K |
|
1017
AXT Inc
AXTI
$4.83B
| $69.3K | ﹤0.01% |
28,858
-1,700
| -6% | -$4.49K |
|
1018
8x8 Inc
EGHT
$324M
| $67.9K | ﹤0.01% |
26,946
+13,600
| +102% | +$48.3K |
|
1019
GeneDx Holdings
WGS
$2.32B
| $67.7K | ﹤0.01% |
18,591
-800
| -4% | -$4.38K |
|
|
ITI
1020
DELISTED
Iteris, Inc.
ITI
| $66.2K | ﹤0.01% |
+16,000
| New | +$68.2K |
|
|
ASRT
1021
DELISTED
Assertio
ASRT
| $65.9K | ﹤0.01% |
1,717
+355
| +26% | +$20.7K |
|
1022
Sutro Biopharma
STRO
$423M
| $65.7K | ﹤0.01% |
1,894
-1,123
| -37% | -$48.9K |
|
1023
Accuray
ARAY
$34.9M
| $65.3K | ﹤0.01% |
+24,000
| New | +$79.1K |
|
|
LONA
1024
LeonaBio Inc
LONA
$70.5M
| $64.5K | ﹤0.01% |
3,192
+320
| +11% | +$8.2K |
|
1025
CarParts.com
PRTS
$51.2M
| $63K | ﹤0.01% |
1,530
-44,567
| -97% | -$1.97M |
|
Similar funds
PFBT
CCP
SP
HCS
SPC
GPCM
MCM
CC
Prelude Capital Management's Q3 2023 Portfolio in Review
As of Q3 2023, Prelude Capital Management held 1,502 positions worth $1.53B, down 0.07% from $1.54B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Prelude Capital Management deployed $46.2M of net new capital in Q3 2023, opening 414 new positions and adding to 344 existing holdings. Its largest new stake was New Relic, Inc.: 130,823 shares worth $11.2M.
By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 14% a quarter earlier, followed by Healthcare and Consumer Discretionary.
On the sell side, the largest reduction was iShares Russell 2000 ETF, an estimated $38.6M trimmed.
- Prelude Capital Management's largest Q3 2023 buy was New Relic, Inc.: 130,823 shares worth $11.2M.
- Prelude Capital Management added most to Alibaba in Q3 2023, an estimated $10.4M increase.
- Prelude Capital Management's biggest Q3 2023 reduction was iShares Russell 2000 ETF, cutting an estimated $38.6M.
- Prelude Capital Management fully exited Green Brick Partners in Q3 2023, selling an estimated $48.6M.
- Prelude Capital Management's ten largest holdings make up 22% of its $1.53B portfolio in Q3 2023.
- Prelude Capital Management opened 414 new positions and closed 396 in Q3 2023.
- Prelude Capital Management's portfolio value fell 0.07% quarter-over-quarter to $1.53B.
Based on Prelude Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.